Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease

Free Radical Biology and Medicine

Volumn 48, Issue 12, 2010, Pages 1570-1576

  Bradley, M A ^a   Markesbery, W R ^a,b   Lovell, M A ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Free radicals; Lipid peroxidation; Oxidative damage; Preclinical Alzheimer disease

Indexed keywords

4 HYDROXYNONENAL; ACROLEIN;

ALZHEIMER DISEASE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IONIZATION; MALE; MASS FRAGMENTOGRAPHY; PRIORITY JOURNAL; PROTEIN CONTENT; SUBICULUM;

ACROLEIN; AGED, 80 AND OVER; ALDEHYDES; ALZHEIMER DISEASE; BRAIN; BRAIN CHEMISTRY; FEMALE; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE;

EID: 77952672909     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.02.016     Document Type: Article

References (44)

1. Mecocci P., MacGarvey U., Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Am. Neurol. Assoc. 1994, 36:747-751.
2. Gabbit S.P., Lovell M.A., Markesbery W.R. Increased nuclear DNA oxidation in the brain in Alzheimer's disease. J. Neurochem. 1998, 71:2034-2040.
3. Nunomura A., Perry G., Pappolla M.A., Wade R., Hirai K., Chiba S., Smith M.A. RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 1999, 19:1959-1964.
4. Shan X., Tashiro H., Lin C.G. The identification and characterization of oxidized RNAs in Alzheimer's disease. J. Neurosci. 2003, 23. 4913-4921.
5. Lovell M.A., Xie C., Markesbery W.R. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res. 2000, 855. 116-123.
6. Lovell M.A., Gabbit S.P., Markesbery W.R. Increased DNA oxidative and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 1999, 72:771-776.
7. Shao C., Xiong S., Li G., Gu L., Mao G., Markesbery W.R., Lovell M.A. Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic. Biol. Med. 2008, 45:813-819.
8. Butterfield D.A., Poon H.F., St.Clair D., Keller J.N., Pierce W.M., Klein J.B., Markesbery W.R. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis. 2006, 22:223-232.
9. Butterfield D.A., Reed T., Perluigi M., De Marco C., Coccia R., Cini C., Sultana R. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci. Lett. 2006, 397:170-173.
10. Gabbit S.P., Aksenov M.Y., Lovell M.A., Markesbery W.R. Decrease in peptide methionine sulfoxide reductase in Alzheimer's disease brain. J. Neurochem. 1999, 73:1660-1666.
11. Sultana R., Boyd-Kimball D., Poon H.F., Cai J., Pierce W.M., Klein J.B., Markesbery W.R., Zhou X.Z., Lu J.P., Butterfield D.A. Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: a redox proteomics analysis. Neurobiol. Aging 2006, 27:918-925.
12. Williams T.I., Lynn B.C., Markesbery W.R., Lovell M.A. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol. Aging 2006, 27:1094-1099.
13. McGarth L.T., McGleenon B.M., Brennan S., McColl D., McIlroy S., Passmore A.P. Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde. Q. J. Med. 2001, 94:385-490.
14. Lovell M.A., Xie C., Markesbery W.R. Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. Neurobiol. Aging 2001, 22:187-194.
15. Markesbery W.R., Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 1998, 19:33-36.
16. Markesbery W.R., Kyyscio R.J., Lovell M.A., Morrow J.D. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann. Neurol. 2005, 58:730-735.
17. Reich E.E., Markesbery W.R., Roberts L.J., Swifte L.L., Morrow J.D., Montine T.J. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease. Am. J. Pathol. 2001, 158:293-297.
18. Wang J., Markesbery W.R., Lovell M.A. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J. Neurochem. 2006, 96:825-832.
19. Ding Q., Markesbery W.R., Chen Q., Keller J.N. Ribosome dysfunction is an early event in Alzheimer's disease. J. Neurosci. 2005, 25:9171-9175.
20. Ding Q., Markesbery W.R., Cecarini V., Keller J.N. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem. Res. 2006, 31:705-710.
21. Shao C., Xiong S., Guo-Min L., Gu L., Mao G., Markesbery W.R., Lovell M.A. Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. Free Radic. Biol. Med. 2008, 45:813-819.
22. Schmitt F.A., Davis D.G., Wekstein D.R., Smith C.D., Ashford J.W., Markesbery W.R "Preclinical" AD revisited: neuropathology of cognitively older adults. Neurology 2000, 55:370-376.
23. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 1991, 11:81-128.
24. Kawai Y., Fujii H., Okada M., Tsuchie U., Uchida K., Osawa T. Formation of Nepsilon-(succinyl)lysine in vivo: a novel marker for docosahexaenoic acid-derived protein modification. J. Lipid Res. 2006, 47:1386-1398.
25. Uchida K., Kanematsu M., Morimitsu Y., Osawa T., Noguchi N., Niki E. Acrolein is a product of lipid peroxidation reaction: formation of free acrolein and its conjugate with lysine residues in oxidized low density lipoproteins. J. Biol. Chem. 1998, 273:16058-16066.
26. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 2003, 42:318-343.
27. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 1998, 23:81-88.
28. Soderberg M., Kristensson E.K., Dallner G. Fatty acid composition of brain phospholipids in aging and Alzheimer's disease. Lipids 1991, 26:421-425.
29. Fitzmaurice P.S., Junchao T., Yazdanpanah M., Liu P.P., Kalasinsky K.S., Kish S.J. Levels of 4-hydroxynonenal and malondialdehyde are increased in brain of human chronic users of methamphetamine. J. Pharmacol. Exp. Ther. 2006, 319:703-709.
30. Saiki R.K., Bugawan T.L., Horn G.T., Mukkis K.B., Erlich H.A. Analysis of enzymatically amplified beta-globin and HLA-DQ alpha DNA with allele-specific oligonucleotide probes. Nature 1986, 324:163-166.
31. Smith C.D., Chebrolu J., Markesbery W.R., Liu J. Improved predictive model for pre-symptomatic mild cognitive impairment and Alzheimer's disease. Neurol. Res. 2008, 30:1091-1096.
32. Braak H., Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991, 82:239-259.
33. Montine K.S., Olson S.J., Amarnath V., Whetsell W.O., Graham D.G., Montine T.J. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4. Am. J. Pathol. 1997, 150:437-443.
34. Calingasan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem. 1999, 72:751-756.
35. Rajamoorthi K., Petrache H.I., McIntosh T.J., Brown M.F. Packing and viscoelasticity of polyunsaturated omega-3 and omega-6 lipid bilayers as seen by 2H NMR and X-ray diffraction. J. Am. Chem. Soc. 2005, 127:1576-1588.
36. Calingansan N.Y., Uchida K., Gibson G.E. Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease. J. Neurochem. 1999, 72:751-756.
37. Nunomura A., Perry G., Aliev G., Hirai K., Takeda A., Balraj E.K. Oxidative damage is the earliest even in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 2001, 60:759-767.
38. Catala A. Lipid peroxidation of membrane phospholipids generates hydroxy-alkenals and oxidized phospholipids active in physiological and/or pathological conditions. Chem. Phys. Lipids 2009, 157:1-11.
39. Lovell M.A., Xie C., Markesbery W.R. Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. Free Radic. Biol. Med. 2000, 29:714-720.
40. Pocernich C.B., Butterfield D.A. Acrolein inhibits NADH-linked mitochondrial enzyme activity: implications for Alzheimer's disease. Neurotox. Res. 2003, 5:515-520.
41. Lovell M.A., Xie C., Markesbery W.R. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease. Neurology 1998, 51:1562-1566.
42. Mattson M.P., Fu W., Waeg G., Uchida K. 4-Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. NeuroReport 1997, 8:2275-2281.
43. Drake J., Petroze R., Castegna A., Ding Q., Keller J.N., Markesbery W.R., Lovell M.A., Butterfield D. A. 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci. Lett. 2004, 356:155-158.
44. Lovell M.A., Gabbita S.P., Markesbery W.R. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J. Neurochem. 1999, 72:771.